Literature DB >> 14661689

Imatinib mesylate-induced interstitial pneumonitis.

Cynthia X Ma, Timothy J Hobday, James R Jett.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14661689     DOI： 10.4065/78.12.1578

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  10 in total

Review 1.  Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

Review 2.  Interstitial lung disease in lung cancer: separating disease progression from treatment effects.

Authors:  Sarah Danson; Fiona Blackhall; Paul Hulse; Malcolm Ranson
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 3.  Infiltrative lung diseases: complications of novel antineoplastic agents in patients with hematological malignancies.

Authors:  Bobbak Vahid; Paul E Marik
Journal:  Can Respir J       Date:  2008 May-Jun       Impact factor: 2.409

Review 4.  Anticancer therapy and lung injury: molecular mechanisms.

Authors:  Li Li; Henry Mok; Pavan Jhaveri; Mark D Bonnen; Andrew G Sikora; N Tony Eissa; Ritsuko U Komaki; Yohannes T Ghebre
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-23       Impact factor: 4.512

5.  Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia.

Authors:  Kirsi Vuorinen; Fei Gao; Tim D Oury; Vuokko L Kinnula; Marjukka Myllärniemi
Journal:  Exp Lung Res       Date:  2007-09       Impact factor: 2.459

6.  Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection.

Authors:  Na-Ri Lee; Ji Won Jang; Hee Sun Kim; Ho-Young Yhim
Journal:  Korean J Intern Med       Date:  2015-06-29       Impact factor: 2.884

Review 7.  European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Authors:  J L Steegmann; M Baccarani; M Breccia; L F Casado; V García-Gutiérrez; A Hochhaus; D-W Kim; T D Kim; H J Khoury; P Le Coutre; J Mayer; D Milojkovic; K Porkka; D Rea; G Rosti; S Saussele; R Hehlmann; R E Clark
Journal:  Leukemia       Date:  2016-04-28       Impact factor: 11.528

8.  A case of imatinib-related obstructive bronchiolitis followed long term.

Authors:  Chika Yajima; Nariaki Kokuho; Kazutoshi Toriyama; Junichiro Kawagoe; Yuki Togashi; Jun Matsubayashi; Hideaki Nakayama; Yasuhiro Setoguchi; Shinji Abe
Journal:  Respir Med Case Rep       Date:  2020-04-04

9.  Nilotinib-induced interstitial lung disease.

Authors:  Se-Il Go; Won Sup Lee; Gyeong-Won Lee; Jung Hun Kang; Myung Hee Kang; Jeong-Hee Lee; Hoon-Gu Kim
Journal:  Int J Hematol       Date:  2013-07-23       Impact factor: 2.490

10.  Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

Authors:  Martin Henkes; Heiko van der Kuip; Walter E Aulitzky
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.